{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-004320","form_type":"8-K","ticker":"NUS","cik":"0001021561","company_name":"NU SKIN ENTERPRISES, INC.","filed_at":"2025-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.718545+00:00","generated_at":"2026-05-26T21:53:34.759661+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Nu Skin Q4 revenue $445.6M, beat guidance; full-year 2025 revenue outlook $1.48-1.62B","bullets":["Q4 GAAP EPS $(0.73); adjusted EPS $0.38 vs $0.37 prior year; revenue down 8.8% YoY.","Full-year 2024 revenue $1.73B (-12%); GAAP EPS $(2.95), adjusted $0.84 vs $1.85.","Rhyz segment Q4 revenue $83.1M (+27.7%); CEO cites improving trends but China/S Korea headwinds.","Q1 2025 guidance: revenue $345-365M, EPS $2.65-2.75 (incl Mavely gain) or $0.10-0.20 ex gain.","Full-year 2025 revenue outlook $1.48-1.62B; adjusted EPS ex-Mavely gain $0.90-1.30."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-004320","json":"https://secwatch.observer/filing/0001140361-25-004320.json","markdown":"https://secwatch.observer/filing/0001140361-25-004320.md","text":"https://secwatch.observer/filing/0001140361-25-004320.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1021561/000114036125004320/0001140361-25-004320-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1021561/000114036125004320/ef20043471_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T21:53:34.759661+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}